Figure 2.
RO pharmacodynamic profiling as evidence of target engagement. CD11b (molecules of equivalent soluble fluorochrome) change from baseline (%) over time. Ven, venetoclax; R, rituximab.

RO pharmacodynamic profiling as evidence of target engagement. CD11b (molecules of equivalent soluble fluorochrome) change from baseline (%) over time. Ven, venetoclax; R, rituximab.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal